


O P F  
OCT 07 2003  
6109  
PENT & TRADEMARK OFFICE


Protective Effect of DPPC and P35 Against  
Challenge of Indomethacin (Indo, 40 mg/kg) and  
Risedronate (100 mg/kg) in Rats



1 P E SC109  
07/2003  
TRADEMARK

Protective Effect of DPPC and P35 Against  
Challenge of Indomethacin (Indo, 40 mg/ kg) and  
Risedronate (100 mg/ kg) in Rats

8-22-02 hg





## Bioavailability of Risedronate (Ris)<sup>a</sup> and PC-Risedronate (PC-Ris)<sup>b</sup> in Rats

	0.5 hour	1 hour	2 hour	4 hour	8 hour	24 hour
Ris	PC-Ris	Ris	PC-Ris	Ris	PC-Ris	Ris
14863	23464	2678	14267	3062	1294	2733
5529	2459	2660	10914	13952	14689	2566
4299	3354	17457	2632	1907	1599	777
16616	2347	5174	2348	7349	5972	1741
34649	8486	1714	3683	1057	6160	15557
1304	2636	1416	11137	983	7340	2326
8011	1262	1283	2165	1347	1217	7264
8733	-----	2085	860	1588	7168	507
						538
11751	6287	4398	6001	3906	5684	2209
±3742	±2997	±1915	±1842	±1615	±1594	4540
						446
						2213*
						101
						133
						±23
						±35

<sup>a</sup> Ris, at a specific activity of 100  $\mu$ Ci/mg was administered to fasted male Sprague Dawley rats (250-300g) at a final dose of 1 mg/kg (or  $\sim 65 \times 10^6$  cpm/rat).


<sup>b</sup> Phospholipon 90 G [containing 93% phosphatidylcholine (PC)] was initially dissolved in chloroform. The solvent was removed by evaporation under nitrogen in tubes to which labeled Ris was added to come to a final PC-Ris formulation at a weight ratio of 1 part Phospholipon 90G: 1 part risedronate.

\* Indicates p<0.05 vs Ris

O I P F  
OCT 07 2003  
SC109  
PATENT & TRADEMARK OFFICE

## Comparison of the Bioavailability of Risedronate and PC-Risedronate in Rats

8-15+8-22-02



OCT 07 2003  
TRADEMARK OFFICE  
SC105

# Bioavailability of C<sup>14</sup>- Risedronate Alone and in Association with PC in Rats Dosed Before and After Feeding


Dose/rat=11.89 x 10<sup>6</sup> ± 0.24

Risedronate-rats fed immediately after dosing (CPM/ml plasma)

<u>Time</u> (hours)	0.5	1	2	4	8	24
	441	229	861	457	87	152
	962	467	458	437	113	82
	<u>18,436</u>	<u>532</u>	<u>894</u>	<u>377</u>	<u>197</u>	<u>43</u>
	534	552	697	324	99	115
	159	4216	157	213	-----	122
	837	1073	945	10648	188	40
	462	795	1135	4985	200	144
	<u>970</u>	<u>273</u>	<u>1493</u>	<u>656</u>	<u>100</u>	<u>197</u>
	<u>2849.9</u>	<u>1016.8</u>	<u>830.2</u>	<u>2811.8</u>	<u>140.3</u>	<u>111.7</u>
	<u>±2228.9</u>	<u>±467.1</u>	<u>±144</u>	<u>±1325.6</u>	<u>±18.2</u>	<u>±19.3</u>

Risedronate:PC-rats fed immediately after dosing (CPM/ml plasma)

<u>Time</u> (hours)	0.5	1	2	4	8	24
	1291	6205	1492	410	134	303
	520	13350	11724	863	192	261
	4463	943	5561	1750	1959	99
	1321	10217	3689	806	354	163
	2132	283	2560	10746	188	115
	1447	393	510	539	119	141
	720	642	1152	636	143	64
	<u>14007</u>	<u>419</u>	<u>5358</u>	<u>214</u>	<u>59</u>	<u>51</u>
	<u>3237.5</u>	<u>4056.3</u>	<u>4005.5</u>	<u>1995.5</u>	<u>393.2</u>	<u>149.5</u>
	<u>±1598.6</u>	<u>±1847.7</u>	<u>±1286.6</u>	<u>±1260.6</u>	<u>±225.7</u>	<u>±32</u>



Risedronate-rats fed 30 minutes before dosing (CPM/ml plasma)

Time (hours)	0.5	1	2	4	8	24
	1605	201	575	155	334	35
	316	1315	446	141	164	19
	486	3618	753	129	181	19
	1291	793	517	162	116	14
	334	450	3285	410	5176	128
	420	404	558	185	211	48
	413	270	647	323	207	44
	<u>538</u>	<u>1194</u>	<u>347</u>	<u>288</u>	<u>261</u>	<u>36</u>
	675.4	1029.5	891	224.1	831.3	42.7
	±173.1	±159.1	±343.2	±36.5	±621.1	±4.3

Risedronate:PC- rats fed 30 minutes before dosing (CPM/ml plasma)

Time (hours)	0.5	1	2	4	8	24
	3479	256	300	261	248	40
	447	180	444	639	201	56
	9917	1849	2004	400	146	59
	2711	273	336	377	229	63
	315	243	450	427	171	71
	2823	271	581	267	295	71
	260	3412	522	498	154	48
	<u>470</u>	<u>218</u>	<u>456</u>	<u>349</u>	<u>214</u>	<u>43</u>
	2552.8	837.8	636.7	402.3	207.3	56.4
	±1151.3	±418.3	±198	±43.9	±17.9	±4.3

RECORDED  
OCT 07 2003  
RECORDED  
PAGE 6013-15-03

### Bioavailability of C<sup>14</sup> - Risedronate Alone and in Association with PC in Rats Dosed Before and After Feeding

